AstraZeneca - Research-Based BioPharmaceutical Company
WEBKeep up to date with the latest news. At AstraZeneca, we’re committed to diving deep into the root cause of heart failure to determine the changes we need to make in ways we treat this disease, transform care and ultimately improve outcomes.
AstraZeneca sets ambition to deliver $80 billion Total Revenue by …
WEBMay 21, 2024 — Today AstraZeneca revealed its bold ambition to deliver $80 billion in Total Revenue by 2030, up from $45.8 billion in 2023. This will be achieved through significant growth in its existing oncology, biopharmaceuticals and rare disease portfolio, and by launching an expected 20 new medicines before the end of the decade.
Media Centre - AstraZeneca
WEBSep 20, 2024 — Medical releases. AstraZeneca Media centre. The Hub for our Articles, Press Releases and Webcasts & Presentations.
AstraZeneca to acquire Fusion to accelerate the development of …
WEBMar 19, 2024 — AstraZeneca has entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing next-generation radioconjugates (RCs). The acquisition marks a major step forward in AstraZeneca delivering on its ambition to transform cancer treatment and outcomes for patients by replacing ...
AstraZeneca to acquire Icosavax, including potential first-in-class …
WEBDec 12, 2023 — The proposed acquisition will build on AstraZeneca’s expertise in respiratory syncytial virus (RSV), strengthening AstraZeneca’s Vaccines & Immune Therapies late-stage pipeline with Icosavax’s lead investigational vaccine candidate, IVX-A12.
AZD1222 vaccine met primary efficacy endpoint in ... - AstraZeneca
WEBNov 23, 2020 — Positive high-level results from an interim analysis of clinical trials of AZD1222 in the UK and Brazil showed the vaccine was highly effective in preventing COVID-19, the primary endpoint, and no hospitalisations or severe cases of the disease were reported in participants receiving the vaccine. There were a …
Full Year and Q4 2023 results - AstraZeneca
WEBFeb 8, 2024 — We expect another year of strong growth in 2024, driven by continued adoption of our medicines across geographies. Our differentiated and growing portfolio of approved medicines, global reach and rich R&D pipeline give us confidence that we will continue to deliver industry-leading growth.”.
Q1 2024 results - AstraZeneca
WEBApr 25, 2024 — “AstraZeneca had a very strong start in 2024 with substantial Total Revenue growth of 19% in the first quarter. Our strong pipeline momentum continued and already this year we announced positive trial results for Imfinzi and Tagrisso that were unprecedented in lung cancer, the data from both of these studies will be presented during the ASCO ...
9M and Q3 2023 results - AstraZeneca
WEB9M and Q3 2023 results. PUBLISHED 9 November 2023. Pascal Soriot, Chief Executive Officer, AstraZeneca, commenting on the results said: “Our company continued its strong growth trajectory in the third quarter with Total Revenue from our non‑COVID-19 medicines up 13% compared to last year.
About Our Company - AstraZeneca
WEBWe are a global, science-led, patient-focused pharmaceutical company. We are dedicated to transforming the future of healthcare by unlocking the power of what science can do for people, society and the planet.
- Some results have been removed